Insights

Gathering insights about SPARC…

Similar companies to SPARC

SPARC Tech Stack

SPARC uses 8 technology products and services including Moat, BootstrapCDN, WordPress, and more. Explore SPARC's tech stack below.

Moat
Analytics
BootstrapCDN
Content Delivery Network
WordPress
Content Management System
Squarespace
Content Management System
Shopify
E-commerce
Font Awesome
Font Scripts
Microsoft
Miscellaneous
Twitter
Widgets

Media & News

Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review
Madrigal Pharmaceuticals (NASDAQ: MDGL - Get Free Report) and SciSparc (NASDAQ: SPRC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk. Earnings and Valuation This table compares Madrigal Pharmaceuticals and
Mar 20, 2026 | www.defenseworld.net
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera's ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).
Mar 16, 2026 | www.globenewswire.com
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
Vancouver, British Columbia – TheNewswire - March 16, 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announces that pursuant to its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.
Mar 16, 2026 | www.thenewswire.com
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease).
Mar 12, 2026 | www.globenewswire.com
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Vancouver, British Columbia – March 11, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). The patent publication highlights the potential of a 5-methoxy-2-aminoindane (MEAI)- Palmitoylethanolamide (PEA) combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population . Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD.
Mar 11, 2026 | www.thenewswire.com
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing of the transaction (the “Transaction”). CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University, in the field of quantum simulation and quantum Monte Claro.
Mar 10, 2026 | www.globenewswire.com
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035 Vancouver, Canada, March 10, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease). This novel therapy integrates Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), provided through its collaboration with NeuroThera Labs Inc. (TSXV: NTLX), a subsidiary of SciSparc Ltd.
Mar 10, 2026 | www.globenewswire.com

SPARC's Email Address Formats

SPARC uses at least 1 format(s):

SPARC Email Formats	Example	Percentage
First@sparcopen.org	John@sparcopen.org	50%
First@sparcopen.org	John@sparcopen.org	50%

Frequently Asked Questions

Where is SPARC's headquarters located?

SPARC's main headquarters is located at 1201 Connecticut Avenue Northwest #608 Washington, District of Columbia 20036 United States. The company has employees across 4 continents, including North AmericaAsiaAfrica.

What is SPARC's stock symbol?

SPARC is a publicly traded company; the company's stock symbol is SPRC.

What is SPARC's official website and social media links?

SPARC's official website is sparcopen.org and has social profiles on LinkedIn.

How much revenue does SPARC generate?

As of March 2026, SPARC's annual revenue is estimated to be $183K.

What is SPARC's SIC code NAICS code?

SPARC's SIC code is 8742 - Management Consulting Services NAICS code is 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations.

How many employees does SPARC have currently?

As of March 2026, SPARC has approximately 32 employees across 4 continents, including North AmericaAsiaAfrica. Key team members include Chief Executive Officer: S. B.Chief Operating Officer: V. A. H.Chief Operating Officer: V. H.. Explore SPARC's employee directory with LeadIQ.

What industry does SPARC belong to?

SPARC operates in the Non-profit Organizations industry.

What technology does SPARC use?

SPARC's tech stack includes MoatBootstrapCDNWordPressSquarespaceShopifyFont AwesomeMicrosoftTwitter.

What is SPARC's email format?

SPARC's email format typically follows the pattern of First@sparcopen.org. Find more SPARC email formats with LeadIQ.

When was SPARC founded?

SPARC was founded in 1998.

SPARC

Q: What is SPARC's official website and social media links?

SPARC's official website is sparcopen.org. SPARC has social profiles on LinkedIn.

Q: How many employees does SPARC have currently?

SPARC has approximately 32 employees.

Q: What technology does SPARC use?

SPARC's tech stack includes RSS, Google Hosted Libraries, Bootstrap, WP Engine, Yoast SEO.

Non-profit OrganizationsDistrict of Columbia, United States11-50 Employees

SPARC is a nonprofit advocacy organization that supports open systems for research and education that enable everyone, everywhere to access, contribute to, and benefit from the knowledge that shapes our world.

Company Overview

Headquarters: 1201 Connecticut Avenue Northwest #608 Washington, District of Columbia 20036 United States
Website: sparcopen.org
SIC Code: 8742 - Management Consulting Services
Stock Symbol: SPRC
NAICS Code: 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations
Founded: 1998
Employees: 11-50

Media & News

Funding & Financials

$10M$25M
SPARC's revenue is estimated to be in the range of $10M$25M

Funding & Financials

$10M$25M
SPARC's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to SPARC

BIOTRONIK

Olympus Corporation

Edwards Lifesciences

St. Jude Medical, Neuromodulation Division

Cardinal Health

Johnson & Johnson

Medtronic

Terumo Corporation

GE HealthCare

Siemens Healthineers

Boston Scientific

SPARC Tech Stack

Media & News

Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

SPARC's Email Address Formats

Frequently Asked Questions

Where is SPARC's headquarters located?

What is SPARC's stock symbol?

What is SPARC's official website and social media links?

How much revenue does SPARC generate?

What is SPARC's SIC code NAICS code?

How many employees does SPARC have currently?

What industry does SPARC belong to?

What technology does SPARC use?

What is SPARC's email format?

When was SPARC founded?

SPARC

Company Overview

Media & News

Madrigal Pharmaceuticals (NASDAQ:MDGL) versus SciSparc (NASDAQ:SPRC) Financial Review

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?